Palisade bio announces oral presentation of phase 2 data at the american college of surgeons (acs) clinical congress 2022

Carlsbad, ca, sept. 29, 2022 (globe newswire) -- palisade bio , inc.  (nasdaq: pali), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (gi) complications, today announced its abstract was accepted for presentation at the american college of surgeons (acs) clinical congress 2022 being held october 16-20, 2022, in san diego, ca.
PALI Ratings Summary
PALI Quant Ranking